http://cimzia.legalview.com/msn/ 2012-02-23 http://cimzia.legalview.com/msn/fda-continues-review-of-cancer-risk-associated-with-tnf-blockers-azath/1330112/ 2012-02-23 http://cimzia.legalview.com/msn/fda-warns-again-of-lymphoma-risk-with-tnf-blockers-in-teens/1330111/ 2012-02-23 http://cimzia.legalview.com/msn/anti-tnf-treatment-linked-to-rare-lymphoma/1330110/ 2012-02-23 http://cimzia.legalview.com/msn/actemra-gains-approval-for-systemic-juvenile-idiopathic-arthritis/1330109/ 2012-02-23 http://cimzia.legalview.com/msn/ahrq-finds-52-increase-in-medication-side-effects-injuries-between-200/1330108/ 2012-02-23 http://cimzia.legalview.com/msn/anti-tnf-treatment-linked-to-rare-lymphoma/1330107/ 2012-02-23 http://cimzia.legalview.com/msn/fda-finds-more-blood-cancer-with-tnf-blocker-drugs/1330106/ 2012-02-23 http://cimzia.legalview.com/msn/abbott-laboratories-earnings-preview/1330105/ 2012-02-23 http://cimzia.legalview.com/msn/earnings-preview-abbott-labs/1330104/ 2012-02-23 http://cimzia.legalview.com/msn/first-ucla-patient-with-hand-transplant-doing-well-at-six-and-a-half-w/1330103/ 2012-02-23 http://cimzia.legalview.com/msn/fresh-from-the-biologic-pipeline2010/1323900/ 2012-02-23 http://cimzia.legalview.com/msn/saa-screening-tool-for-ankylosing-spondylitis-featured-on-abcnewscom/1323899/ 2012-02-23 http://cimzia.legalview.com/msn/cll-patients-receive-biotheras-new-combination-therapy-in-phase-iii-cl/1323898/ 2012-02-23 http://cimzia.legalview.com/msn/buyinsnet-asti-bmr-enzn-usbi-move-expected-to-trade-down-after-bearish/1323897/ 2012-02-23 http://cimzia.legalview.com/msn/boehringer-ingelheim-receives-fda-approval-for-viramune-xr-to-treat-hi/1323896/ 2012-02-23 http://cimzia.legalview.com/msn/nci-awards-mabvax-with-phase-ii-sbir-grant-to-develop-vaccine-against/1323895/ 2012-02-23 http://cimzia.legalview.com/msn/buyinsnet-adi-ain-keg-emn-nktr-layn-are-seasonally-ripe-to-go-up-in-th/1323894/ 2012-02-23 http://cimzia.legalview.com/msn/dont-forget-traditional-dmards-old-friends-are-still-useful/1318311/ 2012-02-23 http://cimzia.legalview.com/msn/abatacept-treatment-for-rheumatoid-arthritis/1318310/ 2012-02-23 http://cimzia.legalview.com/msn/uks-nice-doesnt-back-use-of-bristol-myers-squibbs-orencia/1318309/ 2012-02-23 http://cimzia.legalview.com/msn/mercks-victrelis-phase-iii-study-results-against-hcv-presented-at-easl/1318308/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-phase-2b-top-line-results-glucose-control-not-demonstrated-po/1318307/ 2012-02-23 http://cimzia.legalview.com/msn/buyinsnet-nhi-moh-stem-enzn-arna-edap-are-seasonally-ripe-to-go-down-i/1318306/ 2012-02-23 http://cimzia.legalview.com/msn/biotechnology-stocks-with-persistent-gains-xoma-aria-exel-pdli/1318305/ 2012-02-23 http://cimzia.legalview.com/msn/bristol-myers-arthritis-drug-fails-to-win-backing-of-uk-agency/1318304/ 2012-02-23 http://cimzia.legalview.com/msn/regulus-obtains-exclusive-rights-from-nyu-for-mir-33a-33b-to-treat-met/1318303/ 2012-02-23 http://cimzia.legalview.com/msn/mercks-victrelis-phase-iii-study-results-against-hcv-presented-at-easl/1318302/ 2012-02-23 http://cimzia.legalview.com/msn/pdl-biopharma-expects-1q-revenue-boost/1318301/ 2012-02-23 http://cimzia.legalview.com/msn/bmgp-receives-biotech-development-partners-offer-to-commercialize-opti/1310608/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-ltd-reports-operating-results-10-k/1310607/ 2012-02-23 http://cimzia.legalview.com/msn/saa-screening-tool-for-ankylosing-spondylitis-featured-on-abcnewscom/1310606/ 2012-02-23 http://cimzia.legalview.com/msn/10-k-enzon-pharmaceuticals-inc/1310605/ 2012-02-23 http://cimzia.legalview.com/msn/popular-eni-fiat-telefonica-ucb-european-equity-preview/1310604/ 2012-02-23 http://cimzia.legalview.com/msn/just-released-commercial-insight-disease-modification-in-rheumatoid-ar/1310603/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-phase-2b-top-line-results-glucose-control-not-demonstrated-po/1310602/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-initiates-phase-1-clinical-study-evaluating-nktr-181-a-novel-op/1310601/ 2012-02-23 http://cimzia.legalview.com/msn/iron-deficiency-during-pregnancy-may-impact-childs-brain-development/1310600/ 2012-02-23 http://cimzia.legalview.com/msn/pdl-biopharma-provides-first-quarter-2011-revenue-guidance-of-83-milli/1302764/ 2012-02-23 http://cimzia.legalview.com/msn/pdl-biopharma-expects-1q-revenue-boost/1302763/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-and-pdl-biopharma-resolve-patent-disputes/1302762/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-sells-rights-on-arthritis-drug-for-4-million/1302761/ 2012-02-23 http://cimzia.legalview.com/msn/safety-of-biologic-treatment-for-arthritis-depends-on-the-drug/1296641/ 2012-02-23 http://cimzia.legalview.com/msn/researchers-some-biologics-might-be-more-dangerous-than-others/1296640/ 2012-02-23 http://cimzia.legalview.com/msn/swedens-tlv-confirms-reimbursement-for-qutenza-patch-for-treatment-of/1296639/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-reports-fourth-quarter-and-year-end-2010-financial/1296638/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the/1296637/ 2012-02-23 http://cimzia.legalview.com/msn/night-shift-work-may-reduce-risk-of-skin-cancer-in-women/1296636/ 2012-02-23 http://cimzia.legalview.com/msn/pdl-biopharma-sees-q1-revenues-of-about-83-mln-quick-facts/1296635/ 2012-02-23 http://cimzia.legalview.com/msn/fostamatinib-proven-to-be-safe-but-not-effective/1287931/ 2012-02-23 http://cimzia.legalview.com/msn/when-were-you-diagnosed-with-ra/1287930/ 2012-02-23 http://cimzia.legalview.com/msn/certolizumab-pegol-subcutaneous-route/1287929/ 2012-02-23 http://cimzia.legalview.com/msn/eular-rheumatoid-arthritis-response-quicker-to-certolizumab/1287928/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-and-pdl-biopharma-resolve-patent-disputes/1287927/ 2012-02-23 http://cimzia.legalview.com/msn/global-inflammatory-bowel-disease-therapeutics-industry/1287926/ 2012-02-23 http://cimzia.legalview.com/msn/pdl-ucb-enter-definitive-settlement-agreement-to-resolve-all-legal-pat/1287925/ 2012-02-23 http://cimzia.legalview.com/msn/brief-pdl-biopharm-ucb-resolve-patent-disputes/1287924/ 2012-02-23 http://cimzia.legalview.com/msn/ap-pharma-provides-update-on-response-to-apf530-complete-response-lett/1287923/ 2012-02-23 http://cimzia.legalview.com/msn/doctors-harvesting-antibodies-from-recovered-flu-patients/1287922/ 2012-02-23 http://cimzia.legalview.com/msn/nktr-102-demonstrates-significant-efficacy-as-single-agent-in-second-o/1287921/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the/1271701/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-ltd-is-todays-focus-stock-on-microstockprofitcom/1271700/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-sa-pharmavitae-profile-new-company-profile/1271699/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-to-build-cimzia-capacity-with-333m-swiss-plant/1271698/ 2012-02-23 http://cimzia.legalview.com/msn/these-stocks-could-bounce-xoma-dara-bpax/1268133/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-ltd-reports-operating-results-10-ka/1268132/ 2012-02-23 http://cimzia.legalview.com/msn/nktr-102-demonstrates-significant-efficacy-as-single-agent-in-second-o/1265162/ 2012-02-23 http://cimzia.legalview.com/msn/phase-2-clinical-data-on-nktr-102-in-metastatic-breast-cancer-to-be-pr/1265161/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-starts-lupus-drug-final-trials/1265160/ 2012-02-23 http://cimzia.legalview.com/msn/enbrel-outpaces-humira-in-the-first-three-lines-of-treatment-in-newly/1265159/ 2012-02-23 http://cimzia.legalview.com/msn/newer-anti-tnf-alpha-agents-simponi-and-cimzia-appear-to-be-making-in/1265158/ 2012-02-23 http://cimzia.legalview.com/msn/buyinsnet-otex-enzn-calm-tgb-teso-q-are-seasonally-ripe-to-go-up-in-th/1261314/ 2012-02-23 http://cimzia.legalview.com/msn/update-1-ucb-sees-2-bln-cimzia-despite-rival-pill/1261313/ 2012-02-23 http://cimzia.legalview.com/msn/fda-tnf-alpha-blockers-associated-with-risk-of-fungal-infections/1261312/ 2012-02-23 http://cimzia.legalview.com/msn/fda-cimzia-to-treat-crohns-disease-approved/1261311/ 2012-02-23 http://cimzia.legalview.com/msn/enbrel-outpaces-humira-in-the-first-three-lines-of-treatment-in-newly/1261310/ 2012-02-23 http://cimzia.legalview.com/msn/positive-xoma-052-results-in-inflammatory-eye-disease-behcets-uveitis/1256815/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-3ab-progress-presented-at-national-biodefense-research-meeting/1256814/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-issued-two-new-us-patents-covering-xoma-052/1256813/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-appoints-timothy-p-walbert-to-its-board-of-directors/1256812/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-presentation-and-webcast-at-lazard-capital-markets-7th/1256811/ 2012-02-23 http://cimzia.legalview.com/msn/arthritis-drugs-linked-to-lower-odds-of-alzheimers/1256810/ 2012-02-23 http://cimzia.legalview.com/msn/bristol-myers-squibb-announces-positive-results-from-orencia-trial/1256809/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-presentation-and-webcast-at-lazard-capital-markets-7th/1256808/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-reports-third-quarter-2010-financial-results/1256807/ 2012-02-23 http://cimzia.legalview.com/msn/multiple-stakeholders-come-to-bat-for-large-rheumatoid-arthritis-pgx-t/1256806/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-falls-most-in-six-months-as-ubs-says-takeover-unlikely/1256805/ 2012-02-23 http://cimzia.legalview.com/msn/rapid-and-long-term-clinical-responses-observed-in-rheumatoid-arthriti/1256804/ 2012-02-23 http://cimzia.legalview.com/msn/rheumatoid-arthritis-patient-share-of-actemra-projected-to-exceed-pati/1256803/ 2012-02-23 http://cimzia.legalview.com/msn/anti-tnf-biologic-cimzia-treatment-can-benefit-ra-patients-with-long-s/1256802/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-presents-new-preclinical-data-on-nktr-181-at-anesthesiology-201/1252231/ 2012-02-23 http://cimzia.legalview.com/msn/accor-debenhams-fiat-mobistar-ucb-european-equity-preview/1252230/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-announce-2010-third-quarter-financial-results-and-host-webcast/1252229/ 2012-02-23 http://cimzia.legalview.com/msn/for-the-treatment-of-rheumatoid-arthritis-surveyed-european-rheumatolo/1252228/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-presents-p3-p4-clinical-trial-data-for-crohns-disease-at-acg-scien/1248418/ 2012-02-23 http://cimzia.legalview.com/msn/long-term-data-on-cimzia-certolizumab-pegol-for-moderate-to-severe-cro/1248417/ 2012-02-23 http://cimzia.legalview.com/msn/european-stocks-retreat-barclays-leads-banks-lower-on-capital/1248416/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-ltd-xomad-financial-and-strategic-analysis-review-now-available-a/1248415/ 2012-02-23 http://cimzia.legalview.com/msn/nktr-181-a-mu-opioid-analgesic-with-a-novel-molecular-structure-demons/1248414/ 2012-02-23 http://cimzia.legalview.com/msn/acg-meeting-to-exhibit-cimzia-data-for-crohns-disease-treatment/1248413/ 2012-02-23 http://cimzia.legalview.com/msn/for-the-treatment-of-rheumatoid-arthritis-surveyed-european-rheumatolo/1248412/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-presentation-and-webcast-at-newsmakers-in-the-biotech-i/1248411/ 2012-02-23 http://cimzia.legalview.com/msn/enbrel-humira-and-remicade-will-lose-patient-share-through-2013-accord/1248410/ 2012-02-23 http://cimzia.legalview.com/msn/long-term-data-on-cimzia-certolizumab-pegol-for-moderate-to-severe-cro/1248409/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-phase-2a-trial-enrollment-completed/1244207/ 2012-02-23 http://cimzia.legalview.com/msn/navy-airdrops-dead-drugged-mice-in-battle-with-snake-species/1244206/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-presentation-and-webcast-at-bio-investor-forum/1244205/ 2012-02-23 http://cimzia.legalview.com/msn/despite-dramatic-changes-the-crohns-disease-drug-market-will-experienc/1244204/ 2012-02-23 http://cimzia.legalview.com/msn/russias-rheumatoid-arthritis-drug-market-will-reach-over-470-million-b/1244203/ 2012-02-23 http://cimzia.legalview.com/msn/rapid-and-fast4ward-trials-certolizumab-pegol-for-rheumatoid-arthritis/1244202/ 2012-02-23 http://cimzia.legalview.com/msn/prometheus-tarrot-announce-exclusive-agreement-for-crohns-disease-trea/1240083/ 2012-02-23 http://cimzia.legalview.com/msn/prometheus-tarrot-to-seek-crohns-disease-biomarkers-for-pgx-applicatio/1240082/ 2012-02-23 http://cimzia.legalview.com/msn/dealtalk-savients-gout-drug-nod-may-trigger-bid-war/1240081/ 2012-02-23 http://cimzia.legalview.com/msn/canon-communications-2011-medical-design-excellence-awards-calls-for-e/1240080/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-to-present-at-the-ubs-2010-global-life-sciences-co/1240079/ 2012-02-23 http://cimzia.legalview.com/msn/prometheus-and-tarrot-laboratories-collaborate-to-identify-markers-ass/1240078/ 2012-02-23 http://cimzia.legalview.com/msn/research-and-markets-commercial-insight-inflammatory-bowel-disease-fut/1235848/ 2012-02-23 http://cimzia.legalview.com/msn/fastmoneytalkcom-top-pharmaceutical-stock-picks-pinksheets-axxe-nasdaq/1231976/ 2012-02-23 http://cimzia.legalview.com/msn/tnf-inhibitors-offer-relief-to-arthritis-sufferers/1231975/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-regains-nasdaq-compliance/1231974/ 2012-02-23 http://cimzia.legalview.com/msn/research-and-markets-commercial-insight-inflammatory-bowel-disease-fut/1231973/ 2012-02-23 http://cimzia.legalview.com/msn/inflammatory-bowel-diseases-common-in-area/1231972/ 2012-02-23 http://cimzia.legalview.com/msn/deaths-heighten-arthritis-drugs-warning/1231971/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-reverse-stock-split/1228539/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-appoints-jack-l-wyszomierski-to-its-board-of-directors/1228538/ 2012-02-23 http://cimzia.legalview.com/msn/stemcells-jumps-on-study-sector-indexes-slide/1228537/ 2012-02-23 http://cimzia.legalview.com/msn/reportlinker-adds-commercial-insight-inflammatory-bowel-disease-future/1228536/ 2012-02-23 http://cimzia.legalview.com/msn/mslp-ssnc-xoma-stock-watch-from-bestotccom/1228535/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-sells-rights-on-arthritis-drug-cimzia-for-4-million-to-undisclose/1228534/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-reverse-stock-split/1225023/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-receives-4-million-for-sale-of-royalty-interest-in-cimziar/1225022/ 2012-02-23 http://cimzia.legalview.com/msn/biological-agents-may-help-offset-recurrence-of-crohns-disease/1225021/ 2012-02-23 http://cimzia.legalview.com/msn/cranbourne-patient-reaching-new-heights/1225020/ 2012-02-23 http://cimzia.legalview.com/msn/cwei-sppi-swwc-china-xoma-pgnx-expected-to-be-lower-after-earnings-rel/1225019/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-reverse-stock-split/1225018/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-ltd-xoma-announces-4m-royalty-interest-sale-of-cimzia-provides-no/1225017/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-receives-4-million-for-sale-of-royalty-interest-in-cimziar/1225016/ 2012-02-23 http://cimzia.legalview.com/msn/biological-agents-may-help-offset-recurrence-of-crohns-disease/1221826/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-orphan-drug-designation-for-behcets-disease-recommended-by-eu/1221825/ 2012-02-23 http://cimzia.legalview.com/msn/encouraging-data-on-preventing-crohns-disease-recurrence/1221824/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-reports-second-quarter-2010-financial-results/1221823/ 2012-02-23 http://cimzia.legalview.com/msn/actient-inks-agreement-with-ucb-for-marketed-drugs-with-global-sales-o/1221822/ 2012-02-23 http://cimzia.legalview.com/msn/uk-trust-accuses-ucbs-cimzia-of-infringing-patent/1221821/ 2012-02-23 http://cimzia.legalview.com/msn/top-traded-biotech-stocks-xoma-amgn-biib-ilmn/1218454/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-announce-2010-second-quarter-financial-results-and-host-webcas/1218453/ 2012-02-23 http://cimzia.legalview.com/msn/blastomycosis-in-dogs/1218452/ 2012-02-23 http://cimzia.legalview.com/msn/actient-inks-deal-with-ucb-to-acquire-six-marketed-drugs-with-global-s/1218451/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-designated-orphan-drug-by-fda-for-treatment-of-behcets-diseas/1218450/ 2012-02-23 http://cimzia.legalview.com/msn/arthritis-drugs-get-pbs-listing/1215120/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-receives-750000-milestone-payment-from-aveo-pharmaceuticals/1215119/ 2012-02-23 http://cimzia.legalview.com/msn/cimzia-matches-simponi-on-key-performance-metrics-in-the-treatment-of/1215118/ 2012-02-23 http://cimzia.legalview.com/msn/research-and-markets-pharmaceutical-industry-dynamics-2010-licensing-o/1211291/ 2012-02-23 http://cimzia.legalview.com/msn/nktr-102-demonstrates-superior-activity-to-irinotecan-in-nonclinical-s/1207468/ 2012-02-23 http://cimzia.legalview.com/msn/research-and-markets-formulary-advantages-in-immune-biologics-tighteni/1207467/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-announces-dosing-of-first-patients-in-phase-1-clinical-study-of/1204063/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-achieves-planned-enrollment-goal-for-phase-2b-clinical-trial-of-x/1204062/ 2012-02-23 http://cimzia.legalview.com/msn/fda-finally-admits-that-drugs-for-crohns-disease-and-arthritis-may-pro/1200777/ 2012-02-23 http://cimzia.legalview.com/msn/preclinical-results-with-xoma-052-in-type-2-diabetes-presented-at-amer/1200776/ 2012-02-23 http://cimzia.legalview.com/msn/just-starting-cimzia-anyone-have-any-feedback-on-this-drug/1200775/ 2012-02-23 http://cimzia.legalview.com/msn/newer-medications-helping-patients-with-crohns-disease/1196413/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-host-conference-call-to-present-initial-results-from-xoma-052/1196412/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-announces-positive-initial-results-from-phase-2-st/1196411/ 2012-02-23 http://cimzia.legalview.com/msn/switching-rheumatologists/1196410/ 2012-02-23 http://cimzia.legalview.com/msn/smart-design-receives-2010-medical-design-excellence-award-for-cimzia/1196409/ 2012-02-23 http://cimzia.legalview.com/msn/cimzia-effectiveness/1196408/ 2012-02-23 http://cimzia.legalview.com/msn/nasdaq-grants-xomas-request-for-continued-listing/1196407/ 2012-02-23 http://cimzia.legalview.com/msn/nktr-102-has-high-response-rate-and-sustained-clinical/1192038/ 2012-02-23 http://cimzia.legalview.com/msn/nktr-102-phase-2-clinical-data-accepted-for-oral-presentation-at-2010/1192037/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at/1192036/ 2012-02-23 http://cimzia.legalview.com/msn/boom-time-for-boomer-models/1187902/ 2012-02-23 http://cimzia.legalview.com/msn/certain-arthritis-crohns-drugs-may-raise-kids-cancer-risk-fda/1184939/ 2012-02-23 http://cimzia.legalview.com/msn/trying-cimzia/1184938/ 2012-02-23 http://cimzia.legalview.com/msn/abstract-published-on-initial-results-from-xoma-052-clinical-trial-in/1182387/ 2012-02-23 http://cimzia.legalview.com/msn/osiris-race-to-market-an-fda-approved-stem-cell-product/1182386/ 2012-02-23 http://cimzia.legalview.com/msn/boomers-in-demand-as-models/1182385/ 2012-02-23 http://cimzia.legalview.com/msn/middle-aged-women-becoming-real-role-models/1182384/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-reports-first-quarter-2010-financial-results/1178424/ 2012-02-23 http://cimzia.legalview.com/msn/psoriasis-drug-pipeline-analysis-and-market-forecasts-to-2015/1178423/ 2012-02-23 http://cimzia.legalview.com/msn/biopharma-projects-ltd-appoints-dr-bernard-chan-to-board-of-directors/1178422/ 2012-02-23 http://cimzia.legalview.com/msn/generation-b/1178421/ 2012-02-23 http://cimzia.legalview.com/msn/form-10-q-for-xoma-ltd-de/1178420/ 2012-02-23 http://cimzia.legalview.com/msn/abstract-published-on-initial-results-from-xoma-052/1178419/ 2012-02-23 http://cimzia.legalview.com/msn/despite-safety-concerns-actemra-usage-increases-among/1178418/ 2012-02-23 http://cimzia.legalview.com/msn/fdas-medwatch-safety-alerts-september-2009/1173731/ 2012-02-23 http://cimzia.legalview.com/msn/biologic-medications-for-ra-cimzia-vs-simponi/1173730/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-mechanism-of-action-results-published-in-journal-of/1173729/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-reports-first-quarter-2010/1173728/ 2012-02-23 http://cimzia.legalview.com/msn/osiris-resumes-enrollment-in-stem-cell-trial-for-crohn/1173727/ 2012-02-23 http://cimzia.legalview.com/msn/new-efficacy-data-shows-cimziar-certolizumab-pegol/1173726/ 2012-02-23 http://cimzia.legalview.com/msn/biologic-medications-for-ra-cimzia-vs-simponi/1173725/ 2012-02-23 http://cimzia.legalview.com/msn/long-term-data-on-cimziar-certolizumab-pegol-for-moderate-to/1173724/ 2012-02-23 http://cimzia.legalview.com/msn/brazil-pharmaceuticals-and-healthcare-report-q1-2010-new-market/1170261/ 2012-02-23 http://cimzia.legalview.com/msn/biologicals-continue-to-change-the-therapeutic-picture/1170260/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-announce-2010-first-quarter-financial-results/1170259/ 2012-02-23 http://cimzia.legalview.com/msn/long-term-data-on-cimzia-certolizumab-pegol-for/1170258/ 2012-02-23 http://cimzia.legalview.com/msn/long-term-data-on-cimziar-certolizumab-pegol-for/1170257/ 2012-02-23 http://cimzia.legalview.com/msn/the-gastrointestinal-market-outlook-to-2014-market/1167466/ 2012-02-23 http://cimzia.legalview.com/msn/mme-hires-crystal-zheng-as-digital-media-planner/1167465/ 2012-02-23 http://cimzia.legalview.com/msn/biologic-medications-for-ra-actemra-rituxan-and/1167464/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-shows-potent-in-vitro-inhibition-of/1167463/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-issued-two-new-us-patents-for-methods-of/1164457/ 2012-02-23 http://cimzia.legalview.com/msn/mddi-magazine-selects-39-products-for-medical-design/1164456/ 2012-02-23 http://cimzia.legalview.com/msn/combination-therapy-treats-crohns-disease/1164455/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-ltd-financial-and-strategic-analysis-review/1164454/ 2012-02-23 http://cimzia.legalview.com/msn/what-probability-that-enbrel-causes-auto-immune/1164453/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-receives-1-million-milestone-payment-from-takeda/1164452/ 2012-02-23 http://cimzia.legalview.com/msn/the-gastrointestinal-market-outlook-to-2014-market/1164451/ 2012-02-23 http://cimzia.legalview.com/msn/celgene-sees-drugs-sales-2bln-3bln-in-psoriasis/1161867/ 2012-02-23 http://cimzia.legalview.com/msn/crohns-disease-remicade-prescription-to-decrease/1161866/ 2012-02-23 http://cimzia.legalview.com/msn/orencia-early-leader-among-new-biologics-to-treat/1161865/ 2012-02-23 http://cimzia.legalview.com/msn/data-on-xoma-052-to-be-presented-at-the-american/1161864/ 2012-02-23 http://cimzia.legalview.com/msn/new-arthritis-drug-available-thanks-to-free-trial-for/1158851/ 2012-02-23 http://cimzia.legalview.com/msn/i-have-been-on-humira-for-5-years/1155473/ 2012-02-23 http://cimzia.legalview.com/msn/dont-want-to-take-cimzia/1155472/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-prevents-adverse-cardiac-remodeling-in-animal/1152601/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-052-prevents-adverse-cardiac-remodeling-in-animal/1152600/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at/1148959/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-announces-positive-phase-2-clinical-data-from-first-stage-of/1148958/ 2012-02-23 http://cimzia.legalview.com/msn/zitter-group-hires-vp/1148957/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-announce-2009-and-fourth-quarter-financial-results-and-host/1148956/ 2012-02-23 http://cimzia.legalview.com/msn/enzon-reports-2009-results/1145846/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-initiates-phase-2b-dose-ranging-clinical-trial-of-xoma-052-in/1142832/ 2012-02-23 http://cimzia.legalview.com/msn/reportlinker-adds-ucb-sa-pharmavitae-profile/1142831/ 2012-02-23 http://cimzia.legalview.com/msn/rheumatoid-arthritis-drug-pipeline-analysis-and-market-forecasts/1140996/ 2012-02-23 http://cimzia.legalview.com/msn/viron-granted-us-patents-for-organ-transplant-and-arthritis-drug/1140995/ 2012-02-23 http://cimzia.legalview.com/msn/globaldata-crohns-disease-drug-pipeline-analysis-and-forecasts/1140994/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-reports-removal-of-going-concern-qualification/1140993/ 2012-02-23 http://cimzia.legalview.com/msn/cimzia-draws-even-with-simponi-at-six-months-post-launch-according-to/1140992/ 2012-02-23 http://cimzia.legalview.com/msn/the-year-that-was/1139324/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-appoints-dennis-winger-as-director/1139323/ 2012-02-23 http://cimzia.legalview.com/msn/tnf-alpha-inhibitors-are-being-used-more-often-to-treat-newly/1139322/ 2012-02-23 http://cimzia.legalview.com/msn/dennis-winger-joins-nektar-therapeutics-board-of-directors/1139321/ 2012-02-23 http://cimzia.legalview.com/msn/top-10-new-medications-of-the-year/1139320/ 2012-02-23 http://cimzia.legalview.com/msn/research-and-markets-crohns-disease-a-complete-drug-pipeline/1138427/ 2012-02-23 http://cimzia.legalview.com/msn/decision-resources-reports-increased-uptake-of-tnf-alpha-inhibitors/1138426/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-presents-advantages-of-its-multiple-antibody-formulation/1138425/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-therapeutics-promotes-lorianne-masuoka-md-to-senior-vice/1136364/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-appoints-jim-neal-vice-president-of-business-development/1134362/ 2012-02-23 http://cimzia.legalview.com/msn/spark-highlights-global-design-talent/1132118/ 2012-02-23 http://cimzia.legalview.com/msn/blood-cancer-meeting-abstracts-released-biobuzz/1132117/ 2012-02-23 http://cimzia.legalview.com/msn/zacks-analyst-blog-highlights-enzon-merck-osi-pharmaceuticals/1132116/ 2012-02-23 http://cimzia.legalview.com/msn/new-drug-approved-to-treat-arthritis/1132115/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-presentation-at-lazard-healthcare-conference-on/1132114/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-announce-third-quarter-2009-financial-results-and-host/1130039/ 2012-02-23 http://cimzia.legalview.com/msn/enzon-reports-third-quarter-2009-results/1130038/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-lands-8m-in-rd-technology-deal/1130037/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-expands-development-strategy-for-xoma-052-to-include/1130036/ 2012-02-23 http://cimzia.legalview.com/msn/phase-2-data-from-oral-nktr-118-presented-at-american-college-of/1128323/ 2012-02-23 http://cimzia.legalview.com/msn/the-revolution-in-battling-child-arthritis/1128322/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-to-announce-financial-results-for-the-third-quarter-of/1128321/ 2012-02-23 http://cimzia.legalview.com/msn/new-data-from-cimzia-welcome-trial-to-be-presented-at-the-acg-meeting/1128320/ 2012-02-23 http://cimzia.legalview.com/msn/facts-about-crohns-disease/1128319/ 2012-02-23 http://cimzia.legalview.com/msn/drugs-medications-cimzia-subq/1128318/ 2012-02-23 http://cimzia.legalview.com/msn/new-data-show-cimziar-certolizumab-pegol-provides-sustained-and/1128317/ 2012-02-23 http://cimzia.legalview.com/msn/interim-report-promising-early-results-for-ucbs-new-products/1125874/ 2012-02-23 http://cimzia.legalview.com/msn/drugs-medications-search/1125873/ 2012-02-23 http://cimzia.legalview.com/msn/ucbs-cimziar-certolizumab-pegol-shows-rapid-and-sustained/1125872/ 2012-02-23 http://cimzia.legalview.com/msn/cimzia-the-only-pegylated-anti-tnf-approved-in-europe-and/1125871/ 2012-02-23 http://cimzia.legalview.com/msn/ibm-provides-strategic-it-outsourcing-service-to-s-oil-for-seven-years/1125870/ 2012-02-23 http://cimzia.legalview.com/msn/medications-for-ra-linked-to-skin-cancer/1125869/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-presents-first-xoma-052-cardiovascular-disease-animal-model/1125868/ 2012-02-23 http://cimzia.legalview.com/msn/the-revolution-in-battling-child-arthritis/1125867/ 2012-02-23 http://cimzia.legalview.com/msn/update-1-ucb-sees-new-drug-promise-repeats-2009-outlook/1125866/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-develop-therapeutic-antibody-for-h1n1-and-h5n1-influenza/1123893/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-xoma-announces-plan-to-fully-repay-goldman-sachs-gs-loan/1123892/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-presents-results-demonstrating-novel-mechanism-of-action-for-xoma/1123891/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-and-astrazeneca-form-alliance-for-the-commercialization-of-cimzia/1123890/ 2012-02-23 http://cimzia.legalview.com/msn/reportlinker-adds-monoclonal-antibody-therapeutics-2009-2024/1123889/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-plan-to-fully-repay-goldman-sachs-loan/1122144/ 2012-02-23 http://cimzia.legalview.com/msn/refer-to-a-friend/1122143/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-repay-goldman-loan-biobuzz/1122142/ 2012-02-23 http://cimzia.legalview.com/msn/no-recession-at-oxo/1122141/ 2012-02-23 http://cimzia.legalview.com/msn/pegintron-receives-a-recommendation-for-approval-from-fda-advisory/1122140/ 2012-02-23 http://cimzia.legalview.com/msn/ucbs-cimzia-the-only-pegylated-anti-tnf-approved-in-europe/1122139/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-repay-goldman-sachs-loan/1120403/ 2012-02-23 http://cimzia.legalview.com/msn/prescribing-options-for-treating-inflammation-positioned-to-benefit/1120402/ 2012-02-23 http://cimzia.legalview.com/msn/no-recession-at-oxo/1120401/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-to-develop-therapeutic-antibody-for-h1n1-and-h5n1-influenza/1120400/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-xoma-repays-443-million-loan-to-goldman-sachs-gs/1120399/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-repays-loan-can-fund-operations-into-1q/1120398/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-completes-full-repayment-of-goldman-sachs-loan/1120397/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-and-astrazeneca-form-alliance-for-the-commercialization-of-cimzia/1120396/ 2012-02-23 http://cimzia.legalview.com/msn/fda-updates-warnings-for-tnf-blockers-and-cancer-risk/1118576/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-presents-data-demonstrating-favorable-oral-bioavailability-and/1118575/ 2012-02-23 http://cimzia.legalview.com/msn/market-report-in-play-xoma/1118574/ 2012-02-23 http://cimzia.legalview.com/msn/natural-herbs-can-relieve-many-painful-disorders-and-inflammation/1116625/ 2012-02-23 http://cimzia.legalview.com/msn/scientists-make-sugar-bug-drug-for-bowel-disease/1116624/ 2012-02-23 http://cimzia.legalview.com/msn/helen-of-troy-limited-announces-oxo-houseware-division-and-its/1116623/ 2012-02-23 http://cimzia.legalview.com/msn/arthritis-drugs/1116622/ 2012-02-23 http://cimzia.legalview.com/msn/inflammatory-bowel-disease-new-product-launches/1116621/ 2012-02-23 http://cimzia.legalview.com/msn/fda-posts-qas-on-cancer-risk-with-tnf-blockers-in-children/1116620/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-announces-6-million-antibody-discovery-collaboration-with-arana/1116619/ 2012-02-23 http://cimzia.legalview.com/msn/nektar-announces-ucbs-cimziar-approved-by-us-fda-for-adult/1114922/ 2012-02-23 http://cimzia.legalview.com/msn/fda-warns-on-pediatric-rheumatoid-arthritis-drugs/1114921/ 2012-02-23 http://cimzia.legalview.com/msn/scientists-make-sugar-bug-drug-for-bowel-disease/1114920/ 2012-02-23 http://cimzia.legalview.com/msn/rheumatoid-arthritis-drug-ups-cancer-in-kids/1112450/ 2012-02-23 http://cimzia.legalview.com/msn/cimziar-the-only-pegylated-anti-tnf-recommended-for-approval-in/1112449/ 2012-02-23 http://cimzia.legalview.com/msn/scientists-make-sugar-bug-drug-for-bowel-disease/1112448/ 2012-02-23 http://cimzia.legalview.com/msn/safety-update-on-tnf-blockers/1112447/ 2012-02-23 http://cimzia.legalview.com/msn/helen-of-troy-limited-announces-oxo-houseware-division-and-its-design/1112446/ 2012-02-23 http://cimzia.legalview.com/msn/xoma-licensee-receives-fda-approval-for-cimziar-for-rheumatoid/1108921/ 2012-02-23 http://cimzia.legalview.com/msn/cimzia-approved-for-rheumatoid-arthritis/1108920/ 2012-02-23 http://cimzia.legalview.com/msn/morning-movers-515-xoma-ady-exel-drys-wx-lvs-hig-higher-rgdx/1108919/ 2012-02-23 http://cimzia.legalview.com/msn/new-data-showed-cimziar-provided-rapid-and-sustained-clinical/1108918/ 2012-02-23 http://cimzia.legalview.com/msn/ucb-says-cimzia-recommended-for-approval-in-eu-for-rheumatoid/1108917/ 2012-02-23 http://cimzia.legalview.com/msn/arthritis-drugs-raise-cancer-risk-in-kids-fda/1108916/ 2012-02-23 http://cimzia.legalview.com/msn/cancers-in-children-tied-to-tnf-blockers/1108915/ 2012-02-23 http://cimzia.legalview.com/msn/us-payers-intend-to-limit-preferred-coverage-to-only-one-immune/1108914/ 2012-02-23 http://cimzia.legalview.com/msn/fda-requiring-black-box-warnings-for-certain-arthritis-drugs/1108913/ 2012-02-23 http://cimzia.legalview.com/msn/amgen-and-wyeth-statement-on-fda-announcement-about-tumor-necrosis/1108912/ 2012-02-23 http://cimzia.legalview.com/msn/register-for-free/1108911/ 2012-02-23 http://cimzia.legalview.com/msn/inflammatory-bowel-disease-market-forecast-new-market-report-just/1108910/ 2012-02-23 http://cimzia.legalview.com/msn/certain-arthritis-crohns-drugs-may-raise-kids-cancer-risk-fda/1108909/ 2012-02-23 http://cimzia.legalview.com/msn/rheumatoid-arthritius-drugs-increase-the-risk-of-cancer-and-infection/1108908/ 2012-02-23 http://cimzia.legalview.com/msn/natural-herbs-can-relieve-many-painful-disorders-and-inflammation/1108907/ 2012-02-23 http://cimzia.legalview.com/msn/fda-issues-multiple-safety-alerts-updates/1108906/ 2012-02-23